Compare Stocks: CGON, INSM, BNTX, and INCY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$102.41 -1.3%	$96.13	$79.52 ▼ $124.00	$25.92B	1.29	1.11 million shs	285,684 shs
CGON CG Oncology	$75.06 +0.6%	$73.54	$28.33 ▼ $80.97	$6.64B	0.24	1.11 million shs	52,646 shs
INCY Incyte	$128.30 -0.4%	$120.20	$81.09 ▼ $132.60	$26.01B	0.77	1.73 million shs	214,467 shs
INSM Insmed	$126.36 -0.2%	$114.95	$90.39 ▼ $212.75	$27.59B	0.82	2.98 million shs	723,131 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+1.83%	-7.77%	+12.53%	+15.87%	+3.17%
CGON CG Oncology	-1.67%	-4.88%	+7.87%	+32.98%	+171.63%
INCY Incyte	+3.06%	+0.55%	+8.78%	+27.25%	+49.84%
INSM Insmed	+4.21%	+1.80%	+28.62%	+20.69%	-12.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$102.41 -1.3%	$96.13	$79.52 ▼ $124.00	$25.92B	1.29	1.11 million shs	285,684 shs
CGON CG Oncology	$75.06 +0.6%	$73.54	$28.33 ▼ $80.97	$6.64B	0.24	1.11 million shs	52,646 shs
INCY Incyte	$128.30 -0.4%	$120.20	$81.09 ▼ $132.60	$26.01B	0.77	1.73 million shs	214,467 shs
INSM Insmed	$126.36 -0.2%	$114.95	$90.39 ▼ $212.75	$27.59B	0.82	2.98 million shs	723,131 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+1.83%	-7.77%	+12.53%	+15.87%	+3.17%
CGON CG Oncology	-1.67%	-4.88%	+7.87%	+32.98%	+171.63%
INCY Incyte	+3.06%	+0.55%	+8.78%	+27.25%	+49.84%
INSM Insmed	+4.21%	+1.80%	+28.62%	+20.69%	-12.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.74	Moderate Buy	$127.44	24.44% Upside
CGON CG Oncology	2.77	Moderate Buy	$83.18	10.83% Upside
INCY Incyte	2.56	Moderate Buy	$123.10	-4.06% Downside
INSM Insmed	3.00	Buy	$205.52	62.65% Upside

Current Analyst Ratings Breakdown

Latest CGON, INSM, BNTX, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	INCY Incyte	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
8/31/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$142.00 ➝ $136.00
8/24/2026	INCY Incyte	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/20/2026	INCY Incyte	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	INCY Incyte	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$152.00
8/20/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$150.00
8/17/2026	INCY Incyte	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$110.00 ➝ $130.00
8/13/2026	INCY Incyte	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform	$104.00
8/10/2026	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$185.00 ➝ $195.00
8/10/2026	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/10/2026	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$179.00 ➝ $175.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	7.98	$1.34 per share	76.36	$81.64 per share	1.25
CGON CG Oncology	$4.04M	1,646.75	N/A	N/A	$11.61 per share	6.46
INCY Incyte	$5.14B	5.06	$6.34 per share	20.23	$31.30 per share	4.10
INSM Insmed	$1.14B	24.26	N/A	N/A	$3.47 per share	36.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
INCY Incyte	$1.29B	$7.85	16.34	16.18	3.63	27.71%	29.93%	22.88%	10/27/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	48.41	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)

Latest CGON, INSM, BNTX, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	7.80
CGON CG Oncology	N/A	22.22	22.20
INCY Incyte	N/A	4.59	4.51
INSM Insmed	0.74	3.72	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
CGON CG Oncology	26.56%
INCY Incyte	96.97%
INSM Insmed	N/A

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
CGON CG Oncology	4.80%
INCY Incyte	16.20%
INSM Insmed	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
CGON CG Oncology	61	88.64 million	84.39 million	Optionable
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable

CGON, INSM, BNTX, and INCY Headlines

Recent News About These Companies

Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at ...

4 hours ago | finance.yahoo.com

Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026

September 3 at 7:00 AM | prnewswire.com

Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges?

September 2 at 1:11 PM | insidermonkey.com

Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business

September 2 at 10:20 AM | finance.yahoo.com

Public Employees Retirement System of Ohio Takes $6.52 Million Position in Insmed, Inc. $INSM

September 2 at 5:03 AM | marketbeat.com

Insmed stock trades above $120 as TPIP program advances

September 1 at 9:55 AM | ad-hoc-news.deA

Railway Pension Investments Ltd Takes Position in Insmed, Inc. $INSM

September 1 at 6:00 AM | marketbeat.com

Headlands Technologies LLC Purchases 38,047 Shares of Insmed, Inc. $INSM

August 31 at 4:24 AM | marketbeat.com

Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of "Buy" from Analysts

August 31 at 3:00 AM | americanbankingnews.com

Insmed, Inc. (NASDAQ:INSM) Given Consensus Rating of "Buy" by Brokerages

August 31 at 2:28 AM | marketbeat.com

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

August 27, 2026 | finance.yahoo.com

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

August 27, 2026 | zacks.com

Insmed’s Brinsupri receives Japanese approval to treat patients with non-cystic fibrosis bronchiectasis

August 26, 2026 | pharmabiz.comP

Insmed to Present at September 2026 Investor Conferences

August 26, 2026 | prnewswire.com

Insmed Incorporated (INSM) Stock Price, News, Quote & History - Yahoo Finance

August 25, 2026 | finance.yahoo.com

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic ...

August 24, 2026 | markets.ft.com

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

August 24, 2026 | prnewswire.com

Bank of New York Mellon Corp Makes New $139.97 Million Investment in Insmed, Inc. $INSM

August 24, 2026 | marketbeat.com

13,000 Shares in Insmed, Inc. $INSM Purchased by S&CO Inc.

August 16, 2026 | marketbeat.com

Insmed, Inc. $INSM Shares Bought by Empowered Funds LLC

August 15, 2026 | marketbeat.com

Insmed Inc.

August 14, 2026 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON, INSM, BNTX, and INCY Company Descriptions

BioNTech NASDAQ:BNTX

$102.41 -1.40 (-1.35%)

As of 12:07 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

CG Oncology NASDAQ:CGON

$75.06 +0.47 (+0.62%)

As of 12:07 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Incyte NASDAQ:INCY

$128.30 -0.53 (-0.41%)

As of 12:06 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Insmed NASDAQ:INSM

$126.36 -0.28 (-0.22%)

As of 12:07 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGON, INSM, BNTX, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGON, INSM, BNTX, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGON, INSM, BNTX, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON, INSM, BNTX, and INCY Company Descriptions

BioNTech NASDAQ:BNTX

CG Oncology NASDAQ:CGON

Incyte NASDAQ:INCY

Insmed NASDAQ:INSM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGON, INSM, BNTX, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGON, INSM, BNTX, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGON, INSM, BNTX, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON, INSM, BNTX, and INCY Company Descriptions

BioNTech NASDAQ:BNTX

CG Oncology NASDAQ:CGON

Incyte NASDAQ:INCY

Insmed NASDAQ:INSM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools